
Jan Cerny

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5555278/publications.pdf Version: 2024-02-01



LAN CEDNY

#	Article	IF	CITATIONS
1	A therapeutically targetable mechanism of BCR-ABL–independent imatinib resistance in chronic myeloid leukemia. Science Translational Medicine, 2014, 6, 252ra121.	12.4	105
2	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 726-733.	2.0	71
3	Chromatin remodeling and stem cell theory of relativity. Journal of Cellular Physiology, 2004, 201, 1-16.	4.1	60
4	Incidence, Risk Factors for and Outcomes of Transplantâ€Associated Thrombotic Microangiopathy. British Journal of Haematology, 2020, 189, 1171-1181.	2.5	58
5	Expression of <scp>CD</scp> 25 independently predicts early treatment failure of acute myeloid leukaemia (<scp>AML</scp>). British Journal of Haematology, 2013, 160, 262-266.	2.5	49
6	Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19. Journal of Thrombosis and Thrombolysis, 2021, 51, 657-662.	2.1	48
7	Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors. Haematologica, 2019, 104, 1084-1092.	3.5	46
8	Challenges for management of immune thrombocytopenia during COVIDâ€19 pandemic. Journal of Medical Virology, 2020, 92, 2277-2282.	5.0	43
9	Clinicopathological features of extramedullary recurrence/relapse of multiple myeloma. European Journal of Haematology, 2008, 81, 65-69.	2.2	37
10	COVID-19 pandemic and impact on hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 2193-2195.	2.4	36
11	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Advances, 2018, 2, 2922-2936.	5.2	35
12	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Advances, 2022, 6, 339-357.	5.2	35
13	Mutations in Bone Marrow-Derived Stromal Stem Cells Unmask Latent Malignancy. Stem Cells and Development, 2010, 19, 1153-1166.	2.1	34
14	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, 248-257.	2.0	33
15	Managing sickle cell patients with COVIDâ€19 infection: the need to pool our collective experience. British Journal of Haematology, 2020, 190, e86-e89.	2.5	31
16	Coronary Vasospasm with Myocardial Stunning in a Patient with Colon Cancer Receiving Adjuvant Chemotherapy with FOLFOX Regimen. Clinical Colorectal Cancer, 2009, 8, 55-58.	2.3	28
17	Why Does My Patient Have Leukocytosis?. Hematology/Oncology Clinics of North America, 2012, 26, 303-319.	2.2	24
18	"Because Every Drop Counts― Blood donation during the COVID-19 Pandemic. Transfusion Clinique Et Biologique, 2020, 27, 105-108.	0.4	23

JAN CERNY

#	Article	IF	CITATIONS
19	COVIDâ€19 related immune hemolysis and thrombocytopenia. Journal of Medical Virology, 2021, 93, 1164-1170.	5.0	23
20	Survival outcomes of allogeneic hematopoietic cell transplants with EBVâ€positive or EBVâ€negative postâ€transplant lymphoproliferative disorder, A CIBMTR study. Transplant Infectious Disease, 2019, 21, e13145.	1.7	22
21	Facing COVID-19 in the hematopoietic cell transplant setting: A new challenge for transplantation physicians. Blood Cells, Molecules, and Diseases, 2020, 83, 102439.	1.4	22
22	Mesenchymal Stem Cells in COVID-19: A Journey from Bench to Bedside. Laboratory Medicine, 2021, 52, 24-35.	1.2	22
23	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. Biology of Blood and Marrow Transplantation, 2020, 26, 472-479.	2.0	21
24	PKC Pathways Mediate BCR-ABL-Independent Imatinib Resistance in Chronic Myeloid Leukemia. Blood, 2014, 124, 1790-1790.	1.4	21
25	Effect of ex vivo cytokine treatment on human cord blood engraftment in NOD-scid mice. British Journal of Haematology, 2000, 108, 629-640.	2.5	20
26	Mitoxantroneâ€Induced Cardiotoxicity in Acute Myeloid Leukemia—A Velocity Vector Imaging Analysis. Echocardiography, 2016, 33, 1166-1177.	0.9	20
27	Managing patients with hematological malignancies during COVID-19 pandemic. Expert Review of Hematology, 2020, 13, 787-793.	2.2	20
28	A review on how to do hematology consults during COVID-19 pandemic. Blood Reviews, 2021, 47, 100777.	5.7	20
29	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2017, 23, 269-277.	2.0	19
30	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Advances, 2020, 4, 3180-3190.	5.2	18
31	Convalescent plasma therapy: A passive therapy for an aggressive COVIDâ€19. Journal of Medical Virology, 2020, 92, 2251-2253.	5.0	17
32	The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. Biology of Blood and Marrow Transplantation, 2019, 25, 1325-1330.	2.0	13
33	Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2020, 26, 553-561.	2.0	13
34	The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. Biology of Blood and Marrow Transplantation, 2020, 26, 1137-1143.	2.0	13
35	Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. Biology of Blood and Marrow Transplantation, 2019, 25, 1099-1106.	2.0	12
36	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. Biology of Blood and Marrow Transplantation, 2018, 24, 2443-2449.	2.0	11

JAN CERNY

#	Article	IF	CITATIONS
37	Clinico-genomic profiling and clonal dynamic modeling of <i>TP53</i> -aberrant myelodysplastic syndrome and acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 3348-3360.	1.3	11
38	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clinical Cancer Research, 2019, 25, 5143-5155.	7.0	10
39	Automated red blood cell exchange for acute drug removal in a patient with sirolimus toxicity. Journal of Clinical Apheresis, 2015, 30, 367-370.	1.3	8
40	Elderly do benefit from induction chemotherapy: High dose mitoxantroneâ€based ("5 + 1â€) induction chemotherapy regimen in newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2019, 94, 209-215.	4.1	8
41	Strongyloides stercoralis hyperinfection syndrome in mantle cell lymphoma in post-transplant setting. Annals of Hematology, 2021, 100, 1089-1091.	1.8	8
42	Post-allogeneic hematopoietic stem cell transplantation viral reactivations and viremias: a focused review on human herpesvirus-6, BK virus and adenovirus. Therapeutic Advances in Infectious Disease, 2021, 8, 204993612110180.	1.8	8
43	<i>TP53</i> -mutant myelodysplastic syndrome and acute myeloid leukemia: the black hole of hematology. Blood Advances, 2022, 6, 1917-1918.	5.2	7
44	Novel FGFR3 rearrangement t(4;22)(p16;q11.2) in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma. Annals of Hematology, 2013, 92, 1433-1435.	1.8	5
45	Calcineurin inhibitor-free GVHD prophylaxis with sirolimus and mycophenolate mofetil combination. Annals of Hematology, 2017, 96, 1563-1568.	1.8	5
46	Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 581-586.	2.0	5
47	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>KMT2A</i> -rearranged AML. Blood Advances, 2022, 6, 828-847.	5.2	5
48	Inadequate Cerebrospinal Fluid Concentrations of Available Salvage Agents Further Impedes the Optimal Treatment of Multidrug-Resistant Enterococcus faecium Meningitis and Bacteremia. Infectious Disease Reports, 2021, 13, 843-854.	3.1	5
49	Hematopoietic Cell Transplant (HCT) in the Elderly: Myths, Controversies and Unknowns. Drugs and Aging, 2018, 35, 1055-1064.	2.7	4
50	A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemia. Leukemia and Lymphoma, 2020, 61, 2191-2199.	1.3	4
51	Challenges of Cellular Therapy During the COVID-19 Pandemic. Advances in Experimental Medicine and Biology, 2021, 1318, 657-672.	1.6	4
52	Role of Immunomodulation of BCG Therapy on AML Remission. International Medical Case Reports Journal, 2021, Volume 14, 115-119.	0.8	4
53	Phase 1 Clinical Investigation of Human Myeloid Progenitor Cells (CLT-008) As a Supportive Care Measure during Chemotherapy for Acute Myeloid Leukemia (AML). Blood, 2014, 124, 2268-2268.	1.4	4
54	Early relapse of Burkitt lymphoma heralded by a bone marrow necrosis and numb chin syndrome successfully treated with allogeneic stem cell transplantation. Leukemia Research Reports, 2014, 3, 51-53.	0.4	3

Jan Cerny

#	Article	IF	CITATIONS
55	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplantation and Cellular Therapy, 2022, 28, 187.e1-187.e10.	1.2	3
56	Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. Biology of Blood and Marrow Transplantation, 2018, 24, 1928-1935.	2.0	2
57	Automated red blood cell exchange in preparation for filgrastim mobilization of autologous peripheral blood hematopoietic progenitor cells in a patient with sickle cell anemia. Journal of Clinical Apheresis, 2018, 33, 431-435.	1.3	2
58	Elotuzumab-based maintenance therapy following autologous stem cell transplant in multiple myeloma deepens post-transplant responses. Blood Cells, Molecules, and Diseases, 2020, 85, 102482.	1.4	2
59	Targeted and cytotoxic therapies as maintenance treatment for non-transplant eligible patients with acute myeloid leukemia. Blood Reviews, 2021, 50, 100863.	5.7	2
60	Chronic neutrophilic leukemia, a rare case of leukocytosis. Leukemia Research, 2020, 94, 106384.	0.8	2
61	Rituximab based therapy followed by autologous stem cell transplantation leads to superior outcome and high rates of PCR negativity in patients with indolent B-cell lymphoproliferative disorders. Hematology, 2009, 14, 187-197.	1.5	1
62	Pseudoprogression of triple-hit diffuse large B-cell lymphoma following polatuzumab vedotin-based salvage therapy. Leukemia and Lymphoma, 2021, 62, 2022-2025.	1.3	1
63	High Dose Cyclophosphamide (HDCy) Post Stem Cell Transplant (SCT) Following High Dose Melphalan (HDMel) Based Conditioning As a Dual Strategy For Chemotherapy Dose Intensity and Graft Versus Host Disease (gvhd) Prophylaxis In Matched and Mismatched allogeneic (allo) SCT. Blood, 2013, 122, 4554-4554.	1.4	1
64	High Complete Remission (CR) Rates and Reduced Early Mortality with High Dose Ara-c (HiDAC) and Mitoxantrone (MITO) Induction Chemotherapy for Older (age>60) High Risk Patients with Acute Myeloid Leukemia (AML). Blood, 2010, 116, 3290-3290.	1.4	1
65	A Phase I Dose Finding Trial of Eltrombopag during Consolidation Therapy in Adults with Acute Myeloid Leukemia Employing a Unique Dosing Design: PrE0901, a Precog Study. Blood, 2016, 128, 4053-4053.	1.4	1
66	Extramedullary Acute Myeloid Leukemia of the Renal Pelvis: Insights into a Visceral Niche. Acta Haematologica, 2021, 144, 297-301.	1.4	0
67	Impact of pretransplant mutation status on survival after allogeneic stem cell transplant for acute myeloid leukemia. EJHaem, 2021, 2, 514-519.	1.0	0
68	Mesenchymal Stem Cells (MSC) Promote Aggressive Behavior of Human Breast Cancer Cells (MCF-7) in Vitro- the Role Cytokines (TNF-alpha) and Chemokines. Blood, 2008, 112, 4750-4750.	1.4	0
69	Autologous (Auto) Peripheral Blood Stem Cell (SCT) As a Consolidation Therapy for Patients with Acute Myeloid Leukemia (AML) in 1st Complete Remission (CR): A Single Institution Experience. Blood, 2011, 118, 4505-4505.	1.4	0
70	Unrelated Donor (UD) Cord Blood (CB) Stem Cell Transplantation (SCT) from a Single CB Unit in Older Adults: Excellent Engraftment and Low Early Mortality with a Preparative Regimen of Melphalan (M), Thiotepa (T), Fludarabine(F), and Rabbit (r) Anti Thymocyte Globulin (ATG). Blood, 2014, 124, 1152-1152.	1.4	0
71	Reduced Intensity Conditioning (RIC) Regimens Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML): A Comparison of Fludarabine/Busulfan (FB) and Fludarabine/Melphalan (FM) Based Regimens from the CIBMTR. Blood, 2018, 132, 3456-3456.	1.4	0
72	High Dose Mitoxantrone Based "5+1" Induction Chemotherapy Regimen in Newly Diagnosed Acute Myeloid Leukemia. Blood, 2018, 132, 1430-1430.	1.4	0

Jan Cerny

#	Article	IF	CITATIONS
73	Hematopoeitic Cell Transplant - Comorbidity Index (HCT-CI) Score Is a Useful Tool for Predicting Induction Mortality and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia Patients. Blood, 2018, 132, 1396-1396.	1.4	0
74	A Splenic Infarction Related to Parainfluenza Infection in a Patient with AML: Lessons for COVID-19. Acta Biomedica, 2021, 92, e2021256.	0.3	0
75	A Case of Acute Myeloid Leukemia Harboring a Rare Three-Way Translocation t(5;7;7) Involving the PDGFRB Gene and Successfully Treated with Imatinib. Cancer Management and Research, 2021, Volume 13, 8841-8847.	1.9	0